Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciclesonide Nasal Spray with FP/SAL in PAR
NCT00163488Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2005
- Primary completion
- Aug 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing Ciclesonide + FP/SAL with Placebo + FP/SAL (2 arms). Primary endpoints: Safety and Plasma Cortisol Level at 43 days. Started Jan 2005; status: completed.
02
Drugs
ciclesonide
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00163488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163488.